AtriCure Crescita futura
Criteri Future verificati 3/6
AtriCure prevede che gli utili e i ricavi cresceranno rispettivamente di 51% e 11% all'anno. Si prevede che l'EPS crescerà di 51.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 4.1% in 3 anni.
Informazioni chiave
51.0%
Tasso di crescita degli utili
51.89%
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 16.2% |
| Tasso di crescita dei ricavi | 11.0% |
| Rendimento futuro del capitale proprio | 4.09% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 13 May 2026 |
Aggiornamenti recenti sulla crescita futura
Articolo di analisi • Nov 01
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its quarterly results, which were ahead of market...Articolo di analisi • Aug 01
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
AtriCure, Inc. ( NASDAQ:ATRC ) investors will be delighted, with the company turning in some strong numbers with its...Recent updates
Aggiornamento della narrazione • Jun 03
ATRC: Raised Coverage And P E Outlook Will Support Bullish Repricing
Analysts have raised their AtriCure price target by $2, citing recent supportive research that points to a more constructive view on the stock and its long term assumptions around growth, margins, and future P/E levels. Analyst Commentary Recent research points to a more constructive stance on AtriCure, with bullish analysts emphasizing how current expectations for growth, margins, and future P/E levels could support the stock’s long term investment case.Aggiornamento della narrazione • May 19
ATRC: Product Moat And Clinical Data Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for AtriCure to $55 from $64, reflecting updated assumptions for slightly softer revenue growth, a modestly lower profit margin outlook, and a reduced future P/E multiple, even as recent research points to ongoing product progress and a still supportive view from several firms despite rising competitive concerns. Analyst Commentary Recent research on AtriCure highlights a split in views, with some firms flagging competitive threats and others pointing to ongoing execution in sales, earnings, and product development as support for current valuations.
Aggiornamento della narrazione • May 01
ATRC: Clinical Strength And 2026 Profitability Are Expected To Offset New Competition
The updated analyst price target for AtriCure now reflects a modest valuation reset in the mid to high $50 range, as analysts weigh recent target cuts and rating downgrades against ongoing confidence in the company's product pipeline, clinical data strength, and prospects for durable revenue growth with improving profitability. Analyst Commentary Recent research has introduced a mix of optimism and caution around AtriCure, with bullish views on the product portfolio and clinical positioning sitting alongside fresh concerns about competition and long term growth durability.Aggiornamento della narrazione • Apr 17
ATRC: Clinical Moat And 2026 Profitability Are Expected To Withstand New Entrant
Narrative Update on AtriCure The updated analyst price target for AtriCure has edged down by about $0.23, reflecting a slightly higher discount rate and lower expected future P/E. Analysts are weighing new competitive risks against continued confidence in the company’s product pipeline, clinical data, and profitability progress.Aggiornamento della narrazione • Apr 02
ATRC: 2026 Guidance And Clinical Moat Are Expected To Outlast New Competition
Analysts have modestly reduced the AtriCure price target by $1.31 to $36.41. This reflects both lower published Street targets in response to emerging competition and continued confidence in revenue growth, margins, and the company’s clinical and product positioning.Aggiornamento della narrazione • Mar 19
ATRC: 2026 Guidance And Clinical Moat Will Confront Emerging Competition
Analysts have trimmed AtriCure's average price target by a few dollars to around the mid $50s. This reflects a mix of confidence in recent sales and EPS outperformance and product progress, tempered by concerns about emerging competition in left atrial appendage closure products and long term growth risks.Aggiornamento della narrazione • Mar 04
ATRC: 2026 Guidance And New Dual Energy Platform Will Shape Upside
Analysts have adjusted their outlook on AtriCure, with our updated fair value estimate moving from $36.00 to about $37.72. This change reflects a mix of lower Street price targets, concerns about emerging competition, and continued confidence in the company’s product progress, clinical data, and profitability trajectory.Aggiornamento della narrazione • Feb 18
ATRC: JPMorgan Downgrade And 2026 Profit Outlook Will Shape Risk Balance
Analysts have revised their AtriCure price target from $40.00 to $36.00, citing updated assumptions around discount rates, revenue growth, profit margins, and elevated future P/E expectations in light of recent research, including the JPMorgan downgrade. Analyst Commentary Recent commentary points to a more cautious stance on AtriCure, with the revised US$36.00 target reflecting what bearish analysts see as a need to factor in higher risk around execution, profitability, and future growth expectations.
Aggiornamento della narrazione • Feb 04
ATRC: Dual Energy Platform Trial Progress Will Support Long Term Upside Potential
Analysts have adjusted their price targets on AtriCure, reflecting updated assumptions around discount rates, revenue growth, profit margins and a revised future P/E of 134.36x. Collectively, these factors support a fair value estimate of about $52.78 per share.Aggiornamento della narrazione • Jan 21
ATRC: Future Trial Progress Will Drive Confidence In Long Term Outlook
AtriCure's updated analyst price target has increased from US$50.00 to about US$52.78. Analysts cite adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers of this change.Aggiornamento della narrazione • Jan 06
ATRC: Dual Energy Ablation Breakthrough Will Drive Bullish Repricing
Analysts have maintained their price target on AtriCure at US$64.00, citing updated assumptions for slightly higher revenue growth, wider profit margins, a modestly higher discount rate, and a lower future P/E multiple as key inputs to their valuation work. What's in the News AtriCure announced successful first in human procedures using its dual energy platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, performed at Victorian Heart Hospital in Australia under Monash Health HREC approval (Key Developments).Aggiornamento della narrazione • Dec 15
ATRC: Dual Energy Platform And Noaf Trial Will Drive Bullish Repricing
Analysts have raised their price target on AtriCure by approximately 7 percent to 64 dollars per share, reflecting greater confidence in the company’s improving profit margin outlook and more favorable long term valuation assumptions, despite a slightly higher discount rate. What's in the News AtriCure reported successful first in human procedures with its dual energy ablation platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, achieving box lesion creation and pulmonary vein plus posterior wall isolation in under 60 seconds in the first two patients (company announcement).Articolo di analisi • Dec 11
AtriCure, Inc.'s (NASDAQ:ATRC) 29% Share Price Surge Not Quite Adding Up
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...Articolo di analisi • Nov 01
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its quarterly results, which were ahead of market...Articolo di analisi • Aug 01
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
AtriCure, Inc. ( NASDAQ:ATRC ) investors will be delighted, with the company turning in some strong numbers with its...Articolo di analisi • Jul 08
AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jun 26
AtriCure: Profits And Operating Leverage Are Needed Here
Summary AtriCure has had impressive and sound growth over the past decade. The company has continued to post losses, even though relative losses are coming down. The combination of double-digit sales growth and a 3 times sales multiple looks compelling, yet further margin gains are required to drive appeal here. Read the full article on Seeking AlphaArticolo di analisi • May 01
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch
It's not a stretch to say that AtriCure, Inc.'s ( NASDAQ:ATRC ) price-to-sales (or "P/S") ratio of 3.1x seems quite...Articolo di analisi • Apr 04
Is AtriCure (NASDAQ:ATRC) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Nuova narrazione • Mar 22
cryoSPHERE+ And EnCompass Clamp Launches Will Accelerate Global Adoption
New product launches and international expansion, especially in Europe and China, are key drivers for AtriCure's projected revenue growth and market leadership.Articolo di analisi • Jan 22
Revenues Tell The Story For AtriCure, Inc. (NASDAQ:ATRC) As Its Stock Soars 29%
AtriCure, Inc. ( NASDAQ:ATRC ) shares have continued their recent momentum with a 29% gain in the last month alone...Articolo di analisi • Jan 15
Calculating The Fair Value Of AtriCure, Inc. (NASDAQ:ATRC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$35.69 With US$34.69 share...Articolo di analisi • Dec 24
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Nov 06
A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb
Despite an already strong run, AtriCure, Inc. ( NASDAQ:ATRC ) shares have been powering on, with a gain of 28% in the...Articolo di analisi • Nov 01
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its third-quarter results, which were ahead of...Articolo di analisi • Oct 31
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
AtriCure, Inc. ( NASDAQ:ATRC ), is not the largest company out there, but it saw a significant share price rise of 71...Articolo di analisi • Oct 02
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price
Key Insights AtriCure's estimated fair value is US$39.81 based on 2 Stage Free Cash Flow to Equity Current share price...Articolo di analisi • Sep 06
Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders would be excited to see that the share price has had a great month, posting...Articolo di analisi • Aug 02
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
There's been a notable change in appetite for AtriCure, Inc. ( NASDAQ:ATRC ) shares in the week since its...Seeking Alpha • Jul 25
AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care
Summary AtriCure, Inc. is a market leader in surgical solutions for atrial fibrillation, LAA management, and post-operative pain management, serving 2,000 hospitals globally. AtriCure's latest project involves expanding into the European market with innovative products, facing potential regulatory delays and market acceptance challenges. Despite facing competition from major players like Johnson & Johnson and Medtronic, AtriCure's strong revenue growth and innovative product lineup position it for continued success in the market. Read the full article on Seeking AlphaArticolo di analisi • Jul 18
AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...Articolo di analisi • May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$40.72 AtriCure's US$21.61...Articolo di analisi • Apr 04
Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders won't be pleased to see that the share price has had a very rough month...Articolo di analisi • Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues
When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios (or...Articolo di analisi • Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Sep 27
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights AtriCure's estimated fair value is US$84.48 based on 2 Stage Free Cash Flow to Equity Current share price...Articolo di analisi • Aug 02
Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 763 | 31 | N/A | 115 | 6 |
| 12/31/2027 | 678 | 17 | 41 | 94 | 9 |
| 12/31/2026 | 605 | 3 | 54 | 67 | 9 |
| 3/31/2026 | 552 | -5 | 48 | 64 | N/A |
| 12/31/2025 | 535 | -11 | 42 | 57 | N/A |
| 9/30/2025 | 518 | -29 | 16 | 43 | N/A |
| 6/30/2025 | 500 | -36 | 8 | 36 | N/A |
| 3/31/2025 | 480 | -38 | -1 | 22 | N/A |
| 12/31/2024 | 465 | -45 | -11 | 12 | N/A |
| 9/30/2024 | 448 | -39 | -1 | 10 | N/A |
| 6/30/2024 | 430 | -40 | -20 | -8 | N/A |
| 3/31/2024 | 415 | -37 | -55 | -12 | N/A |
| 12/31/2023 | 399 | -30 | -38 | 4 | N/A |
| 9/30/2023 | 381 | -25 | -43 | 1 | N/A |
| 6/30/2023 | 366 | -28 | -48 | -3 | N/A |
| 3/31/2023 | 349 | -38 | -18 | -2 | N/A |
| 12/31/2022 | 330 | -46 | -39 | -22 | N/A |
| 9/30/2022 | 316 | -56 | -37 | -22 | N/A |
| 6/30/2022 | 303 | 53 | -32 | -20 | N/A |
| 3/31/2022 | 290 | 52 | -41 | -29 | N/A |
| 12/31/2021 | 274 | 50 | -24 | -14 | N/A |
| 9/30/2021 | 259 | 45 | -18 | -10 | N/A |
| 6/30/2021 | 243 | -57 | -14 | -6 | N/A |
| 3/31/2021 | 213 | -49 | -18 | -13 | N/A |
| 12/31/2020 | 207 | -48 | -25 | -20 | N/A |
| 9/30/2020 | 210 | -46 | -36 | -27 | N/A |
| 6/30/2020 | 212 | -50 | -44 | -34 | N/A |
| 3/31/2020 | 230 | -46 | -31 | -18 | N/A |
| 12/31/2019 | 231 | -35 | N/A | -16 | N/A |
| 9/30/2019 | 222 | -23 | N/A | -11 | N/A |
| 6/30/2019 | 216 | -20 | N/A | -3 | N/A |
| 3/31/2019 | 209 | -17 | N/A | -8 | N/A |
| 12/31/2018 | 202 | -21 | N/A | -4 | N/A |
| 9/30/2018 | 195 | -20 | N/A | -4 | N/A |
| 6/30/2018 | 187 | -20 | N/A | -9 | N/A |
| 3/31/2018 | 180 | -27 | N/A | -9 | N/A |
| 12/31/2017 | 175 | -27 | N/A | -9 | N/A |
| 9/30/2017 | 170 | -33 | N/A | -10 | N/A |
| 6/30/2017 | 166 | -32 | N/A | -9 | N/A |
| 3/31/2017 | 160 | -34 | N/A | -14 | N/A |
| 12/31/2016 | 155 | -33 | N/A | -15 | N/A |
| 9/30/2016 | 150 | -36 | N/A | -20 | N/A |
| 6/30/2016 | 143 | -35 | N/A | -18 | N/A |
| 3/31/2016 | 135 | -32 | N/A | -10 | N/A |
| 12/31/2015 | 129 | -27 | N/A | -8 | N/A |
| 9/30/2015 | 123 | -22 | N/A | -6 | N/A |
| 6/30/2015 | 118 | -16 | N/A | -10 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che ATRC diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 3.5% ).
Guadagni vs Mercato: Si prevede che ATRC diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.
Guadagni ad alta crescita: Si prevede ATRC diventerà redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di ATRC ( 11% all'anno) crescerà più lentamente rispetto al mercato US ( 12.5% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di ATRC ( 11% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di ATRC sarà basso tra 3 anni ( 4.1 %).
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/11 07:39 |
| Prezzo dell'azione a fine giornata | 2026/06/11 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
AtriCure, Inc. è coperta da 18 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |